Most patients with Hodgkin lymphoma are cured by modern treatment. For patients with a relapse/refractory disease after autologous stem cell transplantation and brentuximab vedotin, prognosis is dismal. Checkpoint inhibitors are very active in this group of patients and may offer a bridge to allogeneic stem cell transplantation.
(BELG J HEMATOL 2017;8(5):192–4)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
